Search

everythinglearnresearchcommunity

for

Search:↓

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Topical tacrolimus is safe and effective for skin conditions, but oral tacrolimus has serious side effects.

Combining ciclosporin and simvastatin can cause severe kidney damage.

Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

Tacrolimus is a better option than cyclosporine due to fewer side effects.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Acne is not a key diagnostic feature for PCOS, postadolescent men with acne may have insulin resistance, melanoma patients often have few moles, tumor size in CSCC indicates higher risk of serious outcomes, and hidradenitis suppurativa is linked to higher risk of heart problems and death.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Hair samples can reliably monitor tacrolimus levels in kidney transplant patients.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.

Majocchi's granuloma can occur in kidney transplant patients on tacrolimus and can be treated with antifungal medication.

The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.

Ruxolitinib can cause a delayed skin reaction on the nose.

Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

The conclusion is that using drugs to block the TOR pathway might slow aging and prevent age-related diseases.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

Some viruses can cause cancer by changing cell processes and avoiding the immune system; vaccines and targeted treatments help reduce these cancers.

Transplant success has improved with better immunosuppressive drugs and donor matching.

Older age and related diseases increase COVID-19 risk, but anti-aging treatments might help.